ACE Report Cover
Less periprosthetic bone loss with ultra-short stem vs conventional stem in THA at 2 years
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
اللغة
Download Download Download
تحميل
Cite this Report Cite this Report Cite this Report
اقتباس
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ المفضلة
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
اللغة
Download Download Download
تحميل
Cite this Report Cite this Report Cite this Report
اقتباس
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ المفضلة
ARTHROPLASTY
Less periprosthetic bone loss with ultra-short stem vs conventional stem in THA at 2 years .

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2016;4(8):4 Acta Orthop. 2015 Dec;86(6):659-66
المؤلفون المساهمون

M Salemyr O Muren T Ahl H Bodén T Eisler A Stark O Sköldenberg

51 patients with osteoarthritis undergoing total hip arthroplasty were randomized to receive either an uncemented conventional tapered stem or an uncemented ultra-short stem. The purpose of this randomized controlled trial was to compare the different stems in terms of periprosthetic bone loss in the proximal femur, safety, and migration, at 2 years postoperatively. The results suggested that the decrease in periprosthetic bone mineral density (Gruen zone 1 and 1-7) was significantly lower in the ultra-short stem patients. During the first 6 postoperative weeks, the ultra-short stem group displayed greater implant migration, which remained significant at 2 years. Between groups, clinical outcomes were similarly improved at 2 years and adverse events were comparable.


تفاصيل تمويل المنشور +
التمويل:
Industry funded
الراعي:
Ulla and Gustaf Ugglas Stiftelse, Ake Wibergs Stiftelse, Loo and Hans Ostermans Stiftelse, the Sven Noren Foundation, the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, and DePuy Johnsson and Johnsson Foundation for Clinical Research
Conflicts:
Royalties

مخاطر التحيز

6/10

معايير الإبلاغ

18/20

مؤشر الهشاشة

N/A

Was the allocation sequence adequately generated?

Was allocation adequately concealed?

Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?

Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?

Blinding Patients: Was knowledge of the allocated interventions adequately prevented?

Was loss to follow-up (missing outcome data) infrequent?

Are reports of the study free of suggestion of selective outcome reporting?

Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?

Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?

Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?

نعم = 1

غير مؤكد = 0.5

غير ذي صلة = 0

لا = 0

يقيّم تقييم معايير الإبلاغ الشفافية التي يبلغ بها المؤلفون عن الخصائص المنهجية والتجريبية للتجربة في المنشور. ينقسم التقييم إلى خمس فئات معروضة أدناه.

4/4

Randomization

2/4

Outcome Measurements

4/4

Inclusion / Exclusion

4/4

Therapy Description

4/4

Statistics

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

مؤشر الهشاشة هو أداة تساعد في تفسير النتائج المهمة، وتوفر مقياسًا لقوة النتيجة. ويمثل مؤشر الهشاشة عدد الأحداث المتتالية التي يجب إضافتها إلى نتيجة ثنائية التفرع لجعل النتيجة غير مهمة. يمثل الرقم الصغير نتيجة أضعف ويمثل الرقم الكبير نتيجة أقوى.

لماذا كانت هناك حاجة لهذه الدراسة الآن؟

Total hip arthroplasty (THA) is a common procedure in patients with hip osteoarthritis, and there are various prosthetic designs and techniques utilized to minimize the risk of complications and revisions while maintaining excellent patient outcomes. Periprosthetic bone loss in uncemented femoral stems raises concerns of fracture, and shorter femoral stems have gained popularity as they aim to provide a more physiological load pattern in the femur and reduce stress shielding. The absence of a stem that engages the diaphysis of the femur prevents off-loading of the proximal femur, but may also affect the stability necessary for bone integration of the implant. The present study sought to analyze the effects of an ultra-short uncemented stem in patients with osteoarthritis undergoing THA.

ما هو سؤال البحث الرئيسي؟

In patients undergoing total hip arthroplasty for the treatment of osteoarthritis, how did an ultra-short uncemented stem compare to a conventional tapered uncemented stem in terms of periprosthetic bone loss in the proximal femur, safety, and achievement of fixation at 2 years postoperatively?

خصائص الدراسة +
Population:
51 patients (aged 40-70) with primary osteoarthritis scheduled to undergo total hip arthroplasty. Additional inclusion criteria were bone stock suitable for uncemented hip arthroplasty and a femoral anatomy allowing for implantation of either stem type, including no hip dysplasia or previous surgery. Surgery was performed using a posterolateral approach with repair of the posterior capsule and the external rotator muscles. A modular 32mm cobalt-chrome head was used with an uncemented press-fit cup and highly cross-linked ultra-high-molecular weight polyethylene liner. Immediate full weight bearing was allowed.
Intervention:
Ultra-short stem group: Patients received an ultra-short wedge-shaped porous and hydroxyapatite coated titanium stem (Proxima, Depuy). The stem was fully porous-coated with sintered beads, with a mean pore size of 250 um, covered with 30 um highly amorphous hydroxyapatite, and stem length of 71-83mm (n=26, 26 completed; Mean age: 62 +/- 5; 11M/15F).
Comparison:
Conventional stem group: Patients received a proximally porous and hydroxyapatite coated, conventional tapered titanium stem (Bi-metric, Biomet). The stem was proximal 30% porous-coated, with a pore sizes of 100-200 um, covered with plasma-sprayed hydroxyapatite, and stem length of 130-155mm (n=25, 25 completed; Mean age: 62 +/- 6; 11M/14F).
Outcomes:
Primary outcome was the change in femoral periprosthetic bone mineral density (BMD) in Gruen zones 1 and 7 (assessed with dual-energy X-ray absorptiometry [DXA]). Zones 1-2 and 6-7 in the ultra-short stem group were compared to zones 1 and 7, respectively, in the conventional stem group, to account for differences in size of the stems. Secondary outcomes included the change in periprosthetic BMD in the entire periprosthetic region (zones 1-7), stem migration (assessed using radiostereometric analysis [RSA]), and functional clinical results. Clinical outcomes included mid-thigh pain, the Harris Hip Score (HHS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and the EuroQol 5-dimensions (EQ-5D).
Methods:
RCT: prospective.
Time:
Assessments were made preoperatively, and at 2 days, 6 weeks, 3, 6, 12, and 24 months postoperatively.
ما هي النتائج المهمة؟
  • At 2 years, the decrease in BMD in zone 1 was significantly smaller in the ultra-short stem group compared to the conventional group (MD: 18.2% [95% CI 9.5, 26.8]; p<0.001). In zone 7, the decrease in BMD did not significantly differ between groups (MD: 4.5% [95% CI 2.8, 11.8]; p=0.4).
  • At 2 years, the decrease in BMD in the entire periprosthetic region (Zone 1-7), was significantly less in the ultra-short stem group (MD: 5.3% [95% CI 1.5, 9.1]; p=0.02).
  • After 6 weeks postoperative, the ultra-short stems demonstrated significantly median maximum total point motion (1.51mm [0.33-5.44]) compared to the conventional stem group (0.74mm [0.13-5.29]), and significance was maintained up to 2 year follow-up (1.71mm [0.39-6.00] vs. 0.87 [0.87-7.47], respectively; p=0.01). Migration had stopped after 3 months for the majority of components in both groups, and all components were stable at 2 years.
  • Both groups displayed significant improvements from baseline to 2 years postoperatively in the median HHS and WOMAC scores. However, no significant differences were noted in these outcomes between groups (p=0.2 and p=0.5, respectively)
  • The improvement in health-related quality of life (EQ-5D) was similar between groups at 2 years. The number of patients suffering from mid-thigh pain was greater in the conventional group during the first 6 months, without reaching statistical significance at any point.
  • Adverse events were similar between groups (Ultra-short: 45 vs. Conventional: 51). Periprosthetic fracture occurred in one patient in the Ultra-short stem group and periprosthetic infection occurred in one patient in the conventional stem group
ما الذي يجب أن أتذكره أكثر؟

At 2 years, the decrease in periprosthetic bone mineral density in the proximal femur at Gruen zone 1 was significantly lower in the total hip arthroplasty patients who received an uncemented ultra-short stem when compared to a conventional tapered uncemented stem. During the first 6 postoperative weeks, the ultra-short stem group displayed significantly more migration when compared to conventional stems, this difference lasted to the 2 year follow-up. Between groups, all clinical outcomes (HHS, WOMAC, EQ-5D, mid-thigh pain) were similarly improved at 2 years, and adverse events were comparable.

كيف سيؤثر ذلك على رعاية مرضاي؟

The results of this randomized controlled trial suggest that at 2 years, the use of an uncemented ultra-short stem may reduce periprosthetic bone loss in the greater trochanteric region and along the entire preriprosthetic region, though was associated with greater migration early in the follow-up period compared to a conventional stem. Nevertheless, clinical outcome and adverse events did not appear to be affected within this time frame. Further study is warranted given the small evidence base of high-quality literature on the topic, and limited results regarding long-term stability and survivorship between the two designs.

تنويه

هذا المحتوى الموجود في هذه الصفحة هو لأغراض إعلامية فقط وليس الغرض منه أن يكون بديلاً عن المشورة الطبية المتخصصة أو التشخيص أو العلاج. إذا كنت بحاجة إلى علاج طبي، اطلب دائمًا مشورة طبيبك أو اذهب إلى أقرب قسم طوارئ إليك. الآراء والمعتقدات ووجهات النظر التي يعبر عنها الأفراد في المحتوى الموجود في هذه الصفحة لا تعكس آراء ومعتقدات ووجهات نظر أورثوإيفيدنس.

0 من 4 مقالات مجانية شهرية غير مقفلة
لقد وصلت إلى الحد الأقصى لمشاهدة 4 من 4 مقالات مجانية هذا الشهر

ادخل إلى OrthoEvidence مقابل 1.99 دولارًا أمريكيًا في الأسبوع.

ابق على اتصال بأحدث الأدلة. قم بالإلغاء في أي وقت.
  • تقييمات نقدية لأحدث التجارب المعشاة ذات الشواهد عالية التأثير والمراجعات المنهجية في مجال جراحة العظام
  • الوصول إلى محتوى المدونة الصوتية OrthoEvidence، بما في ذلك التعاون مع مجلة جراحة العظام والمفاصل، والمقابلات مع الجراحين المعترف بهم دولياً، ومناقشات المائدة المستديرة حول أخبار وموضوعات جراحة العظام
  • الاشتراك في نشرة The Pulse، وهي نشرة إخبارية مبنية على الأدلة مرتين أسبوعيًا مصممة لمساعدتك على اتخاذ قرارات سريرية أفضل
Upgrade
أهلاً بعودتك!
هل نسيت كلمة المرور؟
ابدأ تجربتك المجانية اليوم!

سيكون حسابك تابعًا لـ
ويتضمن وصولًا مجانيًا إلى OrthoEvidence


أو
هل نسيت كلمة المرور؟

أو
يرجى التحقق من بريدك الإلكتروني

في حالة وجود حساب بعنوان البريد الإلكتروني المقدم، سيتم إرسال بريد إلكتروني لإعادة تعيين كلمة المرور إليك. إذا كنت لا ترى بريدًا إلكترونيًا، يرجى التحقق من مجلد الرسائل غير المرغوب فيها أو البريد غير المرغوب فيه.

لمزيد من المساعدة اتصل بفريق الدعم لدينا.

يرجى تسجيل الدخول لتفعيل هذه الميزة

للوصول إلى هذه الميزة، يجب تسجيل الدخول إلى حساب OrthoEvidence نشط. يرجى تسجيل الدخول أو إنشاء حساب تجريبي مجاني.

ترجمة تقرير ACE

تستخدم OrthoEvidence خدمة ترجمة من طرف ثالث لإتاحة المحتوى بلغات متعددة. يُرجى ملاحظة أنه على الرغم من بذل كل جهد ممكن لضمان الدقة، إلا أن الترجمات قد لا تكون دائمًا مثالية.

كيفية الاستشهاد بهذا ACE Report

OrthoEvidence. Less periprosthetic bone loss with ultra-short stem vs conventional stem in THA at 2 years. OE Journal. 2016;4(8):4. Available from: https://myorthoevidence.com/AceReport/Show/

نسخ الاقتباس
يرجى تسجيل الدخول لتفعيل هذه الميزة

للوصول إلى هذه الميزة، يجب تسجيل الدخول إلى حساب OrthoEvidence نشط. يرجى تسجيل الدخول أو إنشاء حساب تجريبي مجاني.

ميزة العضو المميز

للوصول إلى هذه الميزة، يجب عليك تسجيل الدخول إلى حساب OrthoEvidence المميز.

شارك هذا ACE Report